Citi raised the firm’s price target on Alnylam (ALNY) to $583 from $527 and keeps a Buy rating on the shares after the company announced Phase 2 KARDIA-3 data for zilebesiran in treating uncontrolled hypertension. The firm says that while a single injection brought clinically meaningful reductions of systolic blood pressure at three months that were sustained at six months, it did not reach pre-specified definitions of statistical significance. Citi still believes zilebesiran offers an “intriguing” profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Positive Outlook on Alnylam Pharma’s Hypertension and ATTR-CM Developments
- Cautious Hold Rating on Alnylam Pharma Amid Promising Yet Inconclusive Zilebesiran Trial Results
- Buy Rating for Alnylam Pharma Driven by Promising Zilebesiran Developments and Strategic Partnership with Roche
- Positive Outlook on Alnylam Pharma: Buy Rating Backed by Zilebesiran’s Potential and Amvuttra’s Market Opportunity
- Positive Outlook for Alnylam Pharma Amid Promising Cardiovascular Drug Developments and Strategic Partnerships